SCHEMBL2017497

SCHEMBL2017497

CCCCCCCCCCCCCCCCCCCCCCOc1cc(OC)ccc1CO

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 3/20 0.53
CNR1 P21554 3/20 0.53
MEN1 O00255 1/20 0.48
ALDH1A1 P00352 1/20 0.48
KMT2A Q03164 1/20 0.48
CYSLTR2 Q9NS75 1/20 0.47
CYSLTR1 Q9Y271 1/20 0.47
TSHR P16473 1/20 0.47
NR5A1 Q13285 1/20 0.46
THRA P10827 1/20 0.44
THRB P10828 1/20 0.44
SMPD1 P17405 3/20 0.43
PSEN1 P49768 1/20 0.43
PSEN2 P49810 1/20 0.43
APH1B Q8WW43 1/20 0.43
NCSTN Q92542 1/20 0.43
APH1A Q96BI3 1/20 0.43
PSENEN Q9NZ42 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30775079 0.91 NR5A1 (0.53) CNR2MEN1ALDH1A1KMT2ATSHR
SCHEMBL135802 0.91 NR5A1 (0.53) CNR2MEN1ALDH1A1KMT2ATSHR
SCHEMBL15522362 0.91 NR5A1 (0.53) CNR2MEN1ALDH1A1KMT2ATSHR
SCHEMBL3682775 0.91 NR5A1 (0.53) CNR2MEN1ALDH1A1KMT2ATSHR
SCHEMBL2025290 0.89 CNR1 (0.46) CNR2CNR1MEN1ALDH1A1KMT2A
SCHEMBL10383943 0.88 MTNR1A (0.51) CNR2CNR1CYSLTR2CYSLTR1NR5A1
SCHEMBL20436812 0.88 CNR2 (0.45) CNR2CNR1MEN1ALDH1A1KMT2A
SCHEMBL2018569 0.88 CNR2 (0.45) CNR2CNR1MEN1ALDH1A1KMT2A
SCHEMBL31193480 0.88 CNR2 (0.45) CNR2CNR1MEN1ALDH1A1KMT2A
SCHEMBL31614800 0.87 NR5A1 (0.44) CNR2CNR1MEN1ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2518041-A1 BENZYL COMPOUND Ajinomoto Co., Inc. (JP) 2012-10-31 EP claimed
US-20110160433-A1 BENZYLIC COMPOUND AJINOMOTO CO., INC. (JP) 2011-06-30 US claimed
US-12351601-B2 Method for producing peptide continuously AJINOMOTO CO., INC. (JP) 2025-07-08 US disclosed
US-20250188118-A1 LIQUID PHASE PEPTIDE SYNTHESIS METHODS AMGEN INC. (US) 2025-06-12 US disclosed
WO-2025122535-A2 LIQUID PHASE PEPTIDE SYNTHESIS METHODS AMGEN INC. (US) 2025-06-12 WO disclosed
EP-3778621-B1 PEPTIDE SYNTHESIS METHOD JITSUBO CO LTD (JP) 2023-08-23 EP disclosed
US-20220041648-A1 METHOD FOR PRODUCING PEPTIDE CONTINUOUSLY AJINOMOTO CO., INC. (JP) 2022-02-10 US disclosed
EP-3778621-A1 PEPTIDE SYNTHESIS METHOD Jitsubo Co., Ltd. (JP) 2021-02-17 EP disclosed
EP-3266792-B1 PEPTIDE SYNTHESIS METHOD JITSUBO CO LTD (JP) 2020-12-30 EP disclosed
WO-2020218497-A1 METHOD FOR PRODUCING PEPTIDE CONTINUOUSLY 味の素株式会社 2020-10-29 WO disclosed
US-9334302-B2 Method for removing FMOC group AJINOMOTO CO., INC. (JP) 2016-05-10 US disclosed
US-9206230-B2 Benzylic compound AJINOMOTO CO., INC. (JP) 2015-12-08 US disclosed
US-20140371424-A1 BENZYLIC COMPOUND AJINOMOTO CO., INC. (JP) 2014-12-18 US disclosed
US-8859732-B2 Benzylic compound AJINOMOTO CO., INC. (JP) 2014-10-14 US disclosed
US-20140296483-A1 METHOD FOR REMOVING FMOC GROUP AJINOMOTO CO., INC. (JP) 2014-10-02 US disclosed
EP-2518041-A1 BENZYL COMPOUND Ajinomoto Co., Inc. (JP) 2012-10-31 EP disclosed
US-20110160433-A1 BENZYLIC COMPOUND AJINOMOTO CO., INC. (JP) 2011-06-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250188118-A1 LIQUID PHASE PEPTIDE SYNTHESIS METHODS VIP, RNGTT, SSU72 CNR2 4682/4885CNR1 4670/4885MEN1 1270/4885
US-20220041648-A1 METHOD FOR PRODUCING PEPTIDE CONTINUOUSLY VIP, NPPA, NGLY1 CNR2 4197/4885CNR1 4108/4885MEN1 1477/4885
US-20110160433-A1 BENZYLIC COMPOUND VIP, NGLY1, FURIN CNR2 2139/4885CNR1 2142/4885MEN1 109/4885
US-20140371424-A1 BENZYLIC COMPOUND VIP, NGLY1, FURIN CNR2 2139/4885CNR1 2142/4885MEN1 109/4885
US-20140296483-A1 METHOD FOR REMOVING FMOC GROUP ESD, HM13, FURIN CNR2 2710/4885CNR1 3237/4885MEN1 337/4885
US-12351601-B2 Method for producing peptide continuously VIP, NPPA, NGLY1 CNR2 4197/4885CNR1 4108/4885MEN1 1477/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.